Zur Kurzanzeige

2019-02-27Zeitschriftenartikel DOI: 10.25646/6116
Treatment with Saccharomyces boulardii and Escherichia coli Nissle is safe and associated with reduced nosocomial transmission of vanB vancomycin-resistant Enterococcus faecium on an early rehabilitation ward in Germany: a retrospective analysis
dc.contributor.authorBorgmann, Stefan
dc.contributor.authorRieß, Beate
dc.contributor.authorSiegmund, Rabea
dc.contributor.authorWerner, Guido
dc.contributor.authorKlare, Ingo
dc.date.accessioned2019-04-26T10:53:24Z
dc.date.available2019-04-26T10:53:24Z
dc.date.issued2019-02-27none
dc.identifier.other10.2147/TCRM.S179208
dc.identifier.urihttp://edoc.rki.de/176904/6144
dc.description.abstractPurpose: According to the WHO vancomycin-resistant Enterococcus faecium (VRE) belongs to the microorganisms for which new antibiotics are urgently needed. Depending on the type of vancomycin resistance vanA gene VRE is differentiated from vanB VRE and other types. In this retrospective analysis the results of VRE surveillance performed at a German tertiary hospital with approximately 1,200 beds between 2013 and 2017 are shown. Patients and methods: Rectal screening swabs were taken at admission and once per week on the early rehabilitation ward of Ingolstadt Hospital (ERWIN) but not at other wards. The number of VRE colonized patients was evaluated by using appropriate computer software (LabCentre, Hybase). The Hybase program was also used to find out the number of Saccharomyces boulardii and multi-susceptible Escherichia coli Nissle in blood cultures of patients at ERWIN. The mechanism of vancomycin resistance was examined by PCR and clonality of VRE strains was analyzed by pulsed-field gel electrophoresis. Results: Between 2013 and 2015 the number of VRE increased from 30 to 78 per year whereas in 2016 and 2017 the number declined to 51. Systematic analysis of the laboratory data revealed that this increase was driven by oligoclonal transmission of vanB VRE on ERWIN until August 2016 despite performing intensified infection control measures. However, afterward the number of VRE decreased at ERWIN and subsequently at the other wards. While searching for the reason behind this beneficial development we noticed that at ERWIN, patients treated with antibiotics received two probiotic medications simultaneously (S. boulardii, E. coli Nissle) for the duration of the antibiotic therapy plus an additional 2 days. There was no indication of side effects caused by these microorganisms, particularly no infections. Conclusion: Application of S. boulardii and E. coli Nissle was safe and associated with reduced transmission of VRE from patient to patient at ERWIN. Therefore, in our setting, probiotic treatment of patients receiving antibiotics contributed to the increase of patients’ safety.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectmicrobiotaeng
dc.subjectoligoclonal spreadeng
dc.subjectoutbreakeng
dc.subjectprobioticseng
dc.subjectvanBeng
dc.subjectbacterial spreadeng
dc.subjectcircuit model of bacterial transmissioneng
dc.subjectvanAeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleTreatment with Saccharomyces boulardii and Escherichia coli Nissle is safe and associated with reduced nosocomial transmission of vanB vancomycin-resistant Enterococcus faecium on an early rehabilitation ward in Germany: a retrospective analysisnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6144-1
dc.identifier.doihttp://dx.doi.org/10.25646/6116
dc.type.versionpublishedVersionnone
local.edoc.container-titleTherapeutics and Clinical Risk Managementnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.dovepress.com/treatment-with-saccharomyces-boulardii-and-escherichia-coli-nissle-is--peer-reviewed-article-TCRMnone
local.edoc.container-publisher-namePubMed Centralnone
local.edoc.container-volume2019none
local.edoc.container-issue15none
local.edoc.container-reportyear2019none
local.edoc.container-year2019none
local.edoc.container-firstpage343none
local.edoc.container-lastpage354none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige